OncoMatch/Clinical Trials/NCT04217512
Pantoprazole in Cisplatin Nephrotoxicity
Official title: Possible Protective Effect of Pantoprazole in Cisplatin Induced Nephrotoxicity in Patients With Head and Neck Cancer
Is NCT04217512 recruiting? Yes, currently enrolling (Oct 2026). This Phase 3 trial studies multiple treatments including Pantoprazole low dose and Pantoprazole high dose for oncology.
Treatment: Pantoprazole low dose · Pantoprazole high dose · Cisplatin — Pantoprazole in Cisplatin Nephrotoxicity
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Lab requirements
Kidney function
GFR less than 59 [excluded]
Liver function
Elevated liver enzymes more than 3 fold [excluded]
GFR less than 59. Elevated liver enzymes more than 3 fold.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04217512 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages